Back to results
US 2021/0275540 A1Published application
Treatment of tourette's syndrome with ecopipam
AssigneeEmalex Biosciences, Inc.
InventorsRichard E. Chipkin, Rudolf Kwan
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeEmalex Biosciences, Inc.
InventorsRichard E. Chipkin, Rudolf Kwan
Estimating the term…
The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
-20. (canceled)
A method of treating Tourette's Disorder in a human patient, comprising administering to the patient a dose of ecopipam or a pharmaceutically acceptable salt thereof in a range of 0.1 mg/kg body weight to 5 mg/kg body weight per day.
A method of treating Tourette's Disorder in a human patient, comprising administering to the patient a dose of ecopipam or a pharmaceutically acceptable salt thereof in a range of 50 mg to 500 mg per day.
A method of treating Tourette's Disorder in a human patient not older than 18 years, comprising administering to the patient once daily oral dosages of ecopipam or a pharmaceutically acceptable salt thereof at a daily dose in a range of about 1 mg/kg body weight to about 5 mg/kg body weight.
Dependencies are inferred from the claim text.